

Docket No.: 50193-109

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of

Salah D. KIVLIGHN, et al.

Serial No.: 09/892,505

Group Art Unit: 1614

Filed: June 28, 2001

Examiner:

For: TREATMENT FOR CARDIOVASCULAR DISEASE

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents  
Washington, DC 20231

Dear Sir:

In accordance with the provisions of 37 C.F.R. 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the documents listed on the attached form PTO-1449. It is respectfully requested that the documents be expressly considered during the prosecution of this application, and that the documents be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Supplemental Information Disclosure Statement is being filed within three months of the U.S. filing date OR before the mailing date of a first Office Action on the merits. No certification or fee is required.

Please charge any shortage in fees due in connection with the filing of this paper, including extension of time fees, to Deposit Account 500417 and please credit any excess fees to such deposit account.

Respectfully submitted,

MCDERMOTT, WILL & EMERY

*Robert L. Price*  
Robert L. Price

Registration No. 22,685

600 13<sup>th</sup> Street, N.W.  
Washington, DC 20005-3096  
(202)756-8000 RLP:prp  
Facsimile: (202)756-8087  
**Date: July 22, 2002**

